

Remarks

In preparation for national entry before The United States Patent and Trademark Office (USPTO), Applicants have proposed amending the present application in order to bring the application into conformance with USPTO practice and to more particularly claim the subject matter of the present invention. Applicants courteously request entry of said amendments.


The name provided for Example 29 on page 58 of the specification has been amended so as to remove the phrase “phenyl}” from the name. As would be appreciated by one of skill in the art, this amendment merely corrects a typographical error since the generic scope for the present invention (see the Summary of the Invention, page 3 and Original Claim 1, page 102) does not contemplate nor encompass a quinoline derivative comprising a “phenyl benzamide” functionality at the 7-position of the quinoline ring system.

Original Claims 1-4 have been cancelled and are being replaced with newly submitted Claims 5-14. Basis for the proposed amendments to the claims may be found in the specification. For example, basis for new Claim 5 may be found in original Claim 1 and in the summary of the invention on page 3 (line 11) – page 6 (line 19). Similarly, basis for new Claim 6 may also be found in original Claim 1 as new Claim 6 merely represents a narrowing of the possible values for R1. New Claim 7 has basis in original Claim 1, as well as the specification at page 21(line 11). Basis for new Claim 8 may be found in the specification at page 22(line 32) – page 24(line 10). Basis for new Claim 9 may be found in the specification at page 25(line 27) – page 28(line 13). Basis for new Claim 10 may be found in the specification at page 30(line 5) – page 32(line 2), whereas basis for new Claim 11 may be found at page 34(lines 10 – 23), and basis for new Claim 12 may be found at page 35(lines 5 – 12). Finally, basis for the composition and method claims of new Claims 13 and 14 may be found in the original Claims 2 and 3 as well as the specification at page 7 (lines 1 –

9).

All of the amendments discussed herein either correct typographical errors, narrow the scope of the pending claims, or bring the application into conformance with USPTO practice, thus, it is applicants view that the present amendments do not encompass new matter. Applicants kindly request entry of the amendments proposed herein and consideration upon examination.

Respectfully submitted,



Alexander Wilson  
Attorney for Applicants  
Registration No. 45,782  
Phone: 317-277-0190

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

11 May 2005